EUCTR2007-001165-15-DE进行中（未招募）不适用
Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC) - SIRAC
niversity Hospital of Wuerzburg0 个研究点开始时间: 2007年5月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed diagnosis of ACC
- •Locally advanced or metastatic disease not amenable to radical surgery resection
- •Radiologically monitorable disease
- •Progressing disease after one to three cytotoxic chemotherapy regimes including a platin-based protocol
- •ECOG performance status 0-2
- •Life expectancy = 3 months
- •Age = 18 years
- •Adequate bone marrow reserve (neutrophils = 1500/mm³ and platelets =100.000/mm³, and haemoglobin = 9g/dl)
- •Negative pregnancy test and effective contraception in pre-menopausal female and male patients
- •Patient´s written informed consent
- •Ability to comply with the protocol procedures
- •If patients have been participated in another clinical trial evaluating treatment options for ACC (e.g. FIRM-ACT), the patient can only be included in the SIRAC trial, if:
- •the patient has discontinued study treatment of the previous trial according to the protocol
- •or the study chair of the previous trial gives written approval for inclusion of this individual patient in the SIRAC trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least three years.
- •Severe renal (serum creatinine > 2.5 x ULN) or hepatic insufficiency (ALT / AST > 2.5 x ULN or ALT/AST >5 x ULN if liver function abnormalities are due to the underlying malignancy and/or total serum bilirubin > 2.0 x ULN) and/or serum albumin < 3g/dl
- •Any of the following within the 8 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, or other severe thromboembolic event.
- •Ongoing cardiac dysrhythmias of NCI CTCAE grade ?2, acute atrial fibrillation of any grade, or prolongation of the QTc interval to >470 msec for females
- •Left ventricular ejection fraction (LVEF) ?45% as measured by echocardiogram
- •NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment
- •Hypertension that cannot be controlled by medications (>160/100 mmHg despite optimal medical therapy)
- •Pregnancy or breast feeding
- •Previous treatment with Sunitinib or any other VEGF- or PDGF-pathway directed agent.
- •Current treatment with strong CYP3A4 inhibitors or –inducers
- •Current treatment with another investigational drug
- •Current treatment with another anti-cancer drug
- •Patients with ileus within the last 28 days
- •Major surgery, radiation therapy, or systemic therapy within 3 weeks of first study treatment. At least 7 days should elapse from the time of minor surgical procedure including placement of an access device or fine needle aspiration before start of study treatment
- •Serious wounds that have not completely healed, active ulcer(s), or significant bone fracture(s).
- •Prior radiation therapy to >25% of the bone marrow.
- •Cachectic patients with a body mass index < 18 kg/m2
- •Any other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究者
相似试验
已完成
2 期
Sunitinib in Refractory Adrenocortical CarcinomaAdrenocortical CarcinomaNCT00453895University of Wuerzburg39
已完成
2 期
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical CancerAdrenal Cortex NeoplasmsNCT01255137National Cancer Institute (NCI)13
进行中（未招募）
1 期
Phase 3 study of sunitinib versus placebo in subjects at high risk of recurrent kindey cancerAdjuvant treatment of subjects with high risk” Renal Cell Carcinoma (RCC) following nephrectomy.MedDRA version: 11.0Level: HLTClassification code 10038408Term: Renal cell carcinomasSystem Organ Class: 100000005104EUCTR2006-004024-37-SKPfizer Inc.619
进行中（未招募）
1 期
Phase 3 study of sunitinib versus placebo in subjects at high risk of recurrent kidney cancerAdjuvant treatment of subjects with high risk” Renal Cell Carcinoma (RCC) following nephrectomy.MedDRA version: 11.0Level: HLTClassification code 10038408Term: Renal cell carcinomasSystem Organ Class: 100000004864EUCTR2006-004024-37-IEPfizer Inc. 235 East 42nd Street, New York, 10017619
进行中（未招募）
1 期
Phase 3 study of sunitinib versus placebo in subjects at high risk of recurrent kidney cancerEUCTR2006-004024-37-GBPfizer Inc. 235 East 42nd Street, New York, 10017615